Safety and Effectiveness of Eculizumab throughout Three Pregnancies in a Patient with Refractory Generalized Myasthenia Gravis: A Case Report.

We describe maternal and fetal outcomes in a patient who had three successful pregnancies while being treated with eculizumab for AChR+ gMG. This is a follow-up to our previously published report describing outcomes with this C5 complement inhibitor during the patient's first pregnancy. Eculizumab conferred adequate gMG disease control during these pregnancies, although there were instances of increased gMG symptoms during the first trimester and postpartum period without requirement for rescue therapy.

Chitosan-exosome synergy: Advanced cell-free scaffold approaches for bone tissue engineering.

Bone regeneration and repair, which are hampered by fractures, bone diseases, and trauma, require innovative therapeutic strategies in the field of regenerative medicine. Conventional treatments, such as the use of autologous and allogeneic bone grafts and metal implants, are the primary modalities for bone augmentation in clinical practice; however, they exhibit various limitations. To overcome these limitations, new paradigms, such as exosome-based therapies using chitosan scaffolds, exhibit significant potential for bone tissue engineering.

Rare coagulation factor deficiencies: a five-year experience from a single tertiary care center in South India.

Objective: Rare coagulation factor deficiencies (RCFD) comprise a heterogeneous class of coagulation disorders due to deficiencies/abnormalities in coagulation factors other than factors VIII, IX and von Willebrand factor (VWF). Due to its rarity and varying geographic prevalence, bleeding characteristics and behaviour pattern are not known. Our aim was to study the frequency and clinical profile of RCFD, assess the severity of deficiency, evaluate blood component requirements and surgical outcomes.

Assessing neoadjuvant chemotherapy's impact on complications following radical cystectomy.

Introduction: Despite level 1 evidence supporting neoadjuvant chemotherapy (NACT) followed by radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC), its adoption is hindered by concerns about toxicity and detrimental impact on post-RC complications. We retrospectively reviewed post-RC complications at a tertiary care hospital, particularly assessing impact of NACT.

Methods: Data from the institutional bladder cancer database were retrieved for patients aged ≥18 with MIBC (≥American Joint Committee on Cancer Clinical Stage T2), treated with RC between May 2013 and July 2023.